Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MTrix

Financiado

Cerrado

Mechanical Targeting as an Integrative Approach for Personalized Nanomedicine

The ability to direct drug delivery to specific tissues is a central challenge in treating diseases as it determines the balance between drug selectivity and toxicity. Clinical drug failures, commonly due to safety issues or poor... ver más

31/05/2023

THE HEBREW UNIVERS...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-05-31

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

THE HEBREW UNIVERSITY OF JER...

1.50M€ | Lider

LABORATORIOS BELLOCH

192.85K€ | Participante

Proyectos interesantes

CPP2021-008946

Medical Technol...

Nanotechnology

616K€ Cerrado

REACT

Nanotechnology

Medical Technol...

1M€ Cerrado

SMARTRIOX

Medical Technol...

Nanotechnology

3M€ Cerrado

OatLive

Medical Technol...

Nanotechnology

150K€ Cerrado

PCI2021-122091-2B

Medical Technol...

Nanotechnology

161K€ Cerrado

CTQ2015-73234-JIN

Medical Technol...

Nanotechnology

204K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 66 meses Fecha Inicio: 2017-11-15
Fecha Fin: 2023-05-31

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The ability to direct drug delivery to specific tissues is a central challenge in treating diseases as it determines the balance between drug selectivity and toxicity. Clinical drug failures, commonly due to safety issues or poor efficacy, are extremely costly to the pharmaceutical industry. In light of this, there is a global effort to develop Targeted Drug Delivery Systems (DDS) and Nanomedicine-based drugs to increase the therapeutic efficacy of a drug while substantially reducing its off-target exposure. In oncology, this issue is critical since chemotherapies have poor selectivity, thus causing severe side effects due to undesired systemic exposure. However, the enormous heterogeneity and dynamic nature of tumors makes it extremely challenging to identify universal target molecules. In this ERC I introduce a novel concept according to which the specificity of DDS can be dramatically enhanced by tuning the physical parameters of DDS based on mechanical cues of target and non-target cells. In many cancers, it is well-established that the flexibility and deformability of cells are correlated with their metastatic potential. This leads to our hypothesis that the enhanced deformability of cancer cells allows them to engulf and uptake particles whose internalization requires massive shape change, unlike the stiffer and normal cells. The rationale of the proposed study is that by considering physical parameters of cells, the mechanical properties of DDS can be tuned to achieve selective uptake. We thus propose to develop tools for rational design of DDS for personalized nanomedicine that will use simple tests performed on a patient’s own cells. This is the basis of our visionary Mechanical Targeting (MT) scheme, a crosstalk between experimental and computational models, for drug specificity. Accordingly, this ERC is expected to yield breakthroughs, both conceptual and technical.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores